# US 5,703,046 A · Treatment method using recombinantly produced human membrane cofactor protein (MCP)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,703,046 A
- Document ID: US5703046A
- Status: Granted
- Kind: A
- Application number: 08/476,713
- Filed: 1995-06-07
- Granted: 1997-12-30
- Earliest claimed: 1989-07-21
- Assignees: Washington University
- Inventors: John P. Atkinson
- Web page: https://patentgrep.com/patent/US5703046A

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/18: against material from animals or humans
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y10S 435/81: Packaged device or kit
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Human membrane cofactor protein, a protein involved in regulation of complement activity, has been purified to homogeneity. The gene encoding this protein has been retrieved and permits deduction of the entire amino acid sequence and the recombinant production of this material. Pharmaceutical compositions in which MCP is the active ingredient for use in treating antoimmune diseases are also disclosed.

## Claims

### Claim 1

A method to treat a disease or condition characterized by enhanced complement activity, which method comprises administering to a subject in need of such treatment an effective amount of isolated human membrane cofactor protein encoded by a DNA which hybridizes under stringent conditions to the complement of the DNA encoding amino acids 1-251 of FIG. 1 expressed in a non-human or human recombinant host cell in admixture with a suitable pharmaceutical excipient.

### Claim 2 (depends on 1)

The method of claim 1 wherein the membrane cofactor protein has the amino acid sequence shown in FIG. 1 from amino acid residues 1 to 350 or an alternatively spliced version of this amino acid sequence.

### Claim 3 (depends on 1)

The method of claim 1 wherein the host is selected from the group consisting of procaryotic cells, yeast cells, avian cells, and insect cells.

### Claim 4 (depends on 1)

The method of claim 1 wherein the membrane cofactor protein is isolated from the surface of a non-human or human recombinant host cell that does not normally express membrane cofactor protein.

### Claim 5 (depends on 1)

The method of claim 1 wherein the membrane cofactor protein contains one or two conservative substitutions of the amino acid sequence shown as amino acids 1-251 of FIG. 1.

### Claim 6 (depends on 1)

The method of claim 1 wherein the disease or condition is characterized by inflammation.